TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.

MLA

Borelli, Beatrice, et al. “TRIPLETE: A Randomised Phase III Study of Modified FOLFOXIRI plus Panitumumab versus MFOLFOX6 plus Panitumumab as Initial Therapy for Patients with Unresectable RAS and BRAF Wild-Type Metastatic Colorectal Cancer.” ESMO Open, vol. 3, no. 4, July 2018, p. e000403. EBSCOhost, https://doi.org/10.1136/esmoopen-2018-000403.

APA

Borelli, B., Moretto, R., Lonardi, S., Bonetti, A., Antoniotti, C., Pietrantonio, F., Masi, G., Burgio, V., Marmorino, F., Salvatore, L., Rossini, D., Zaniboni, A., Zucchelli, G., Martignetti, A., Di Battista, M., Pella, N., Passardi, A., Boccaccino, A., Leone, F., … Falcone, A. (2018). TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. ESMO Open, 3(4), e000403. https://doi.org/10.1136/esmoopen-2018-000403

Chicago

Borelli, Beatrice, Roberto Moretto, Sara Lonardi, Andrea Bonetti, Carlotta Antoniotti, Filippo Pietrantonio, Gianluca Masi, et al. 2018. “TRIPLETE: A Randomised Phase III Study of Modified FOLFOXIRI plus Panitumumab versus MFOLFOX6 plus Panitumumab as Initial Therapy for Patients with Unresectable RAS and BRAF Wild-Type Metastatic Colorectal Cancer.” ESMO Open 3 (4): e000403. doi:10.1136/esmoopen-2018-000403.